Ayanbola Elegbe

584 citations
22 papers · 424 · h-index 8

Impact in

  • Rheumatology top 5%
    • Rheumatoid Arthritis Research and Therapies
    • Systemic Lupus Erythematosus Research
  • Hematology top 10%
    • Autoimmune and Inflammatory Disorders Research

Papers in

  • Rheumatology 9
    • Rheumatoid Arthritis Research and Therapies 7
    • Systemic Lupus Erythematosus Research 3
  • Genetics 7
    • Chronic Lymphocytic Leukemia Research 7
    • Inflammatory Bowel Disease 3
Co-authors
Michael Schiff (4 shared papers)Michael A. Maldonado (5 shared papers)R. Valente (5 shared papers)Gustavo Citera (2 shared papers)Roy Fleischmann (2 shared papers)Michael E. Weinblatt (2 shared papers)Désirée van der Heijde (1 shared paper)Mark C. Genovese (4 shared papers)
Journals
Annals of the Rheumatic Diseases (6 papers)Journal of Crohn s and Colitis (3 papers)Journal of Clinical Oncology (2 papers)Arthritis Care & Research (2 papers)The Journal of Rheumatology (2 papers)
Partner nations
United StatesGermanyArgentina

In The Last Decade

Ayanbola Elegbe

22 papers receiving 409 citations

Peers

Ayanbola Elegbe
Comparison fields: 5 of 51
  • Rheumatology 308
  • Hematology 142
  • Genetics 104
  • Immunology 116
  • Pathology and Forensic Medicine 80
Replace Fedra Irazoque-Palazuelos with:
Fedra Irazoque-Palazuelos Mexico
Riitta Koivuniemi Finland
Ravi Rao United Kingdom
Sheila Kelly United States
X. Mariette France
Mirjam K. de Vries Netherlands
Nicola Tyson United Kingdom
H-P Tony Germany
E. Becerra Spain
Sabrina Rebello United States
Ayanbola Elegbe relative to Fedra Irazoque-Palazuelos Mexico Fedra Irazoque-Palazuelos's profile →
Citations per field
00.5×1.7×
Fedra Irazoque-Palazuelos · 1×
Citations per year

Countries citing papers authored by Ayanbola Elegbe

Since Specialization
Citations

This map shows the geographic impact of Ayanbola Elegbe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ayanbola Elegbe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ayanbola Elegbe more than expected).

Fields of papers citing papers by Ayanbola Elegbe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ayanbola Elegbe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ayanbola Elegbe. The network helps show where Ayanbola Elegbe may publish in the future.

Co-authors

The 25 scholars most cited alongside Ayanbola Elegbe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ayanbola Elegbe Line = papers co-authored together Ayanbola Elegbe links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
Annals of the Rheumatic Diseases ·Michael Schiff, Michael E. Weinblatt, R. Valente, Désirée van der Heijde, Gustavo Citera, Ayanbola Elegbe, Michael A. Maldonado, Roy Fleischmann
2013208
2
Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel‐Arm, Open‐Label Study
Arthritis Care & Research ·Peter Nash, S. Nayiager, Mark C. Genovese, Alan Kivitz, Kurt Oelke, Charles Ludivico, William Palmer, Cristian Rodriguez, I. Delaet, Ayanbola Elegbe, M Corbo
201261
3
Longterm Safety and Efficacy of Abatacept Through 5 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy
The Journal of Rheumatology ·Mark C. Genovese, Michael Schiff, Michael E. Luggen, Manuela Le Bars, Richard Aranda, Ayanbola Elegbe, Maxime Dougados
201252
4
Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial
The Journal of Rheumatology ·Mark C. Genovese, César Pacheco‐Tena, A. Covarrubias, Gustavo León, Eduardo Mysler, Mauro Waldemar Keiserman, R. Valente, Peter Nash, Jesus Abraham Simón Campos, J. Box, Clarence W. Legerton, Е. Л. Насонов, Patrick Durez, Ayanbola Elegbe, Robert Wong, Xiaohui Li, Subhashis Banerjee, Rieke Alten
201821
5
Randomized Clinical Trial Design to Assess Abatacept in Resistant Nephrotic Syndrome
Kidney International Reports ·Howard Trachtman, Debbie S. Gipson, Michael J.G. Somers, Cathie Spino, Sharon G. Adler, Lawrence B. Holzman, Jeffrey B. Kopp, John R. Sedor, Sandra Overfield, Ayanbola Elegbe, Michael A. Maldonado, Anna Greka
201717
6
DOP45 Long-term cardiac safety of ozanimod in phase 3 clinical program of Ulcerative Colitis and relapsing multiple sclerosis
Journal of Crohn s and Colitis ·Alessandro Armuzzi, Raymond K. Cross, Gary R. Lichtenstein, Jonathan Calkwood, Ajit B. Pai, Marc Pondel, (unknown), Lorna Charles, Ayanbola Elegbe, A Petersen, James K. Sheffield, Adil Javed, Jason K. Hou, Miguel Regueiro, Douglas C. Wolf, Millie D. Long
20229
7
OP0253 A phase iii randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of abatacept or placebo on standard of care in patients with active class iii or iv lupus nephritis
Annals of the Rheumatic Diseases ·Richard Furie, M.A. Dooley, David Wofsy, Tsutomu Takeuchi, Ana Malvar, Andrea Doria, Juanita Romero‐Díaz, Tak Mao Chan, Ayanbola Elegbe, Gerald B. Appel, David Jayne, Michael A. Maldonado
20189
8
A phase II, randomized study of nivolumab (nivo) or nivo plus BMS-986205 with or without intravesical Bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC): CheckMate 9UT.
Journal of Clinical Oncology ·Noah M. Hahn, Sam S. Chang, Maxwell V. Meng, Neal D. Shore, Badrinath R. Konety, Gary D. Steinberg, Juergen E. Gschwend, Hiroyuki Nishiyama, Juan Palou Redorta, John A. Taylor, Ayanbola Elegbe, Alexandre Lambert, Li Zhu, Yuko Ishii, Toshiki Maeda, Bradley Raybold, Gary D. Grossfeld, Bruce S. Fischer, Mark Rutstein, Alfred Witjes
20198
9
A phase 3 randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± BMS-986205 in cisplatin-eligible muscle invasive bladder cancer (MIBC).
Journal of Clinical Oncology ·Guru Sonpavde, Andrea Necchi, Shilpa Gupta, Gary D. Steinberg, Juergen E. Gschwend, Michiel Simon Van Der Heijden, Nathalie Garzon, Ayanbola Elegbe, Bradley Raybold, Danny Liaw, Mark Rutstein, Matt D. Galsky
20197
10
P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis
The American Journal of Gastroenterology ·Millie Long, Raymond K. Cross, Jonathan Calkwood, Marc Pondel, Ashwini Pai, (unknown), Lorna Charles, Ayanbola Elegbe, AnnKatrin Petersen, James K. Sheffield, Adil Javed, Douglas C. Wolf
20216
11
OP0044 Head-To-Head Comparison of Subcutaneous Abatacept Versus Adalimumab on Background Methotrexate in RA: Two Year Results from the Ample Study
Annals of the Rheumatic Diseases ·Michael Schiff, Michael E. Weinblatt, R. Valente, D. van der Heijde, Gustavo Citera, Ayanbola Elegbe, Michael A. Maldonado, Roy Fleischmann
20135
12
A phase 2, randomized study of nivolumab or nivolumab plus BMS-986205 with or without intravesical bacillus Calmette-Guerin in patients with bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer: CheckMate 9UT
European Urology Supplements ·J.A. Witjes, J. Gschwend, J. Palou, Mei Meng, Sam S. Chang, Neal D. Shore, Badrinath R. Konety, Gregory R. Steinberg, Hiroyuki Nishiyama, Jack A. Taylor, Ayanbola Elegbe, Alexandre Lambert, Liangru Zhu, Y Ishii, Toshiki Maeda, Bradley Raybold, Gary D. Grossfeld, Barbara Fischer, Mark Rutstein, Noah M. Hahn
20194
13
P316 Ozanimod is an efficacious oral therapy after, 5-ASA failure in immunomodulator- and biologic-naive patients with ulcerative colitis: post hoc analysis from True North
Journal of Crohn s and Colitis ·B E Sands, Axel Dignaß, Peter M. Irving, Michael Chiorean, Millie D. Long, Dilek Eren, (unknown), Mark T. Osterman, A Petersen, Ayanbola Elegbe, Timothy E. Ritter, Silvio Danese
20223
14
Rate of Anti-Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor Seroconversion in Patients with Undifferentiated Arthritis or Early Rheumatoid Arthritis Treated with Abatacept.
Data Archiving and Networked Services (DANS) ·T. Huizinga, P. Emery, René Westhovens, Manuela Le Bars, Corine Gaillez, Coralie Poncet, Ayanbola Elegbe, Josef S Smolen
20112
15
THE EFFICACY AND SAFETY OF SUBCUTANEOUS (SC) ABATACEPT (ABA) WITH OR WITHOUT MTX IN PATIENTS WITH ACTIVE RA
Internal Medicine Journal ·Peter Nash, S. Nayiager, M. C. Genovese, C. Rodriguez, Delaet, Ayanbola Elegbe, M Corbo, Tiffany L Bamford
20112
16
15: LONG-TERM CARDIAC SAFETY OF OZANIMOD IN PHASE 3 CLINICAL PROGRAM OF ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS
Gastroenterology ·Millie D. Long, Raymond Cross, Gary R. Lichtenstein, Jonathan Calkwood, Ashwini Pai, Marc Pondel, (unknown), Lorna Charles, Ayanbola Elegbe, AnnKatrin Petersen, James K. Sheffield, Adil Javed, Jason K. Hou, Miguel Regueiro, Douglas C. Wolf, Alessandro Armuzzi
20222
17
FRI0193 SC vs IV abatacept in RA: post-hoc efficacy analysis of long-term acquire (SC) data with aim (IV) data
Annals of the Rheumatic Diseases ·M. C. Genovese, C. Pacheco Tena, A. Covarrubias Cobos, G. Léon, Eduardo Mysler, M. Keiserman, R. Valente, Peter Nash, Jesus Abraham Simón Campos, J. Box, Clarence W. Legerton, Е. Л. Насонов, Patrick Durez, I. Delaet, Ayanbola Elegbe, Rieke Alten
20122
18
P431 Early mucosal healing at week, 10 with ozanimod predicts clinical outcomes at week, 52: Post hoc analysis of the phase, 3 True North clinical trial
Journal of Crohn s and Colitis ·Walter Reinisch, Jordan E. Axelrad, (unknown), Marc Pondel, Shabana Ather, Ayanbola Elegbe, Charles A. Sninsky, Randy Longman
20222
19
Improvements in Patient‐Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial
Arthritis Care & Research ·Vibeke Strand, Laure Gossec, Laura C. Coates, Alexis Ogdie, Jiyoon Choi, Brandon Becker, Joe Zhuo, Thomas Lehman, Miroslawa Nowak, Ayanbola Elegbe, Philip J. Mease, Atul Deodhar
20241
20
FRI0227 Five-Year Safety and Efficacy of Subcutaneous Abatacept in Patients with Moderate To Severely Active RA and An Inadequate Response To MTX: Long-Term Extension of The Phase III, Double-Blind, Randomized Acquire Study
Annals of the Rheumatic Diseases ·Mark C. Genovese, C. Pacheco Tena, A. Covarrubias, G. Léon, Eduardo Mysler, M. Keiserman, R. Valente, Peter Nash, Jesus Abraham Simón Campos, J. Box, Clarence W. Legerton, Е. Л. Насонов, Patrick Durez, Ayanbola Elegbe, Robert Wong, X. Li, Susana Banerjee, Rieke Alten
20161

About Ayanbola Elegbe

Ayanbola Elegbe is a scholar working on Rheumatology, Genetics, Pathology and Forensic Medicine, Hematology and Surgery, having authored 22 papers that have together received 424 indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (7 papers), Chronic Lymphocytic Leukemia Research (7 papers), Lymphoma Diagnosis and Treatment (4 papers), Inflammatory Bowel Disease (3 papers), Autoimmune and Inflammatory Disorders Research (3 papers), Bladder and Urothelial Cancer Treatments (3 papers), Systemic Lupus Erythematosus Research (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). The work is most often cited by research in Rheumatology (308 citations), Hematology (142 citations), Genetics (104 citations), Immunology (116 citations) and Pathology and Forensic Medicine (80 citations). Ayanbola Elegbe has collaborated with scholars based in United States, Germany and Argentina. Frequent co-authors include Michael Schiff, Michael A. Maldonado, R. Valente, Gustavo Citera, Roy Fleischmann, Michael E. Weinblatt, Désirée van der Heijde, Mark C. Genovese, Manuela Le Bars and Maxime Dougados. Their work appears in journals such as Annals of the Rheumatic Diseases, Journal of Crohn s and Colitis, Journal of Clinical Oncology, Arthritis Care & Research and The Journal of Rheumatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fedra Irazoque-PalazuelosBreakdown of academic impact, for papers by Riitta KoivuniemiBreakdown of academic impact, for papers by Ravi RaoBreakdown of academic impact, for papers by Sheila KellyBreakdown of academic impact, for papers by X. MarietteBreakdown of academic impact, for papers by Mirjam K. de VriesBreakdown of academic impact, for papers by Nicola TysonBreakdown of academic impact, for papers by H-P TonyBreakdown of academic impact, for papers by E. BecerraBreakdown of academic impact, for papers by Sabrina Rebello